Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials
grantDOI: https://doi.org/10.48105/CTF.CTF-2023-10-003.pc.gr.175365 studyName: Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials dataStatus: Data Pending initiative: Clinical Research Award studyLeads: Vanessa Merker studyStatus: Active diseaseFocus: Neurofibromatosis type 2 grantEndDate: 1759190400000 institutions: Massachusetts General Hospital fundingAgency: CTF manifestation: Quality of Life embargoEndDate: 1790726400000 grantStartDate: 1696118400000 studyFileviewId: syn53181393 syn53181386 syn53181387 syn53181393 syn53181388
Drop files to upload
Demonstrating Clinical Benefit of New Treatments for NF2-related schwannomatosis - Developing A More Comprehensive and Sensitive Measure of Quality of Life for NF2 Clinical Trials page is loading…